Drug Profile
NVX 408
Alternative Names: NVX-408Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator NuvOx Pharma
- Class Fluorocarbons
- Mechanism of Action Oxygen carriers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemorrhage; Haemorrhagic shock
Most Recent Events
- 04 Sep 2023 Preclinical development in Haemorrhage in USA (IV, Injection). (NuvOx Pharma pipeline; September 2023)
- 04 Sep 2023 Preclinical development is ongoing in Haemorrhagic shock in USA (IV, Injection). (NuvOx Pharma pipeline; September 2023)
- 28 Feb 2021 No recent reports of development identified for preclinical development in Haemorrhage in USA (IV, Injection)